

Bioretec Ltd

DECISIONS OF BIORETEC OY'S EXTRAORDINARY GENERAL MEETING ON JULY 9, 2021

Extraordinary general meeting of Bioretec Oy was held at July 9, 2021 in Tampere. Meeting notice was published at company internet pages on June 22, 2021. Present at the meeting or represented by way of proxy representation in total were 3.704.167 shares representing 34.46% on number of shares and votes.

Authorization of the Board of Directors to resolve on the issuance of options

Extraordinary general meeting resolved based on the proposal to authorize Bioretec Board of Directors to resolve on option program, based on which option rights shall be granted to Springvest Oy and its tied agents in relation the terms of the agreement between the company and Springvest Oy concerning the organizing of a financing round for the company. Based on the authorization the maximum number of shares that can be subscribed based on the option rights shall be 384,000 shares. Share subscription price of the shares to be subscribed based on the option rights shall be EUR 0,001 per share.

The authorization shall be valid until the 31 December 2021 and it does not cancel the previous authorizations granted to the Board of Directors.

Authorization of the Board of Directors to resolve on the issuance of shares

Extraordinary general meeting resolved based on the proposal to authorize Bioretec Board of Directors to resolve on the issuance of the shares. Under the authorization, up to 1,333,333 shares can be issued. The shares can be issued in one or more tranches against minimum subscription price of EUR 3.00 per share. The shares issued under the authorization can be new shares or shares in the company's possession. The authorization can be used to strengthen the balance sheet and financial position of the company or for other purposes determined by the Board of Directors. Under the authorization, the Board of Directors may resolve upon issuing new shares, without consideration, to the company itself. The Board of Directors is authorized to resolve on all other terms for share issues. The Board of Directors is authorized to resolve on a directed share issue, provided, that there is a weighty financial reason for the company to do so.

The authorization is valid until the end of the next Annual General Meeting, however, no longer than until 30 June 2022. The authorization shall revoke previous unused share issue authorizations except for the authorization pursuant to section 6 and the authorization granted by the Annual General Meeting held on 26 June 2020 authorizing the Option Program 2020-1.

Minutes of the general meeting

Minutes of the extraordinary general meeting can be delivered to shareholders on request (IR@bioretec.com). Meeting minutes are also visible at Bioretec Oy headquarters at Yrittäjänkulma 5, 33710 Tampere.

Further enquiries

Timo Lehtonen, CEO, tel. +358 50 433 8493

Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132

Information about Bioretec

Bioretec Ltd is a medical device company focusing on the development of strong, safe and reliable bioresorbable implants for pediatric and adult orthopedics. The company develops, manufactures and commercializes innovative bioresorbable orthopedic implants and materials for bone and soft tissue injuries. Bioretec's products are used worldwide, and the company continues to further develop materials and products for high load-bearing clinical applications. Based in Tampere, Finland, Bioretec employs 24 dedicated professionals, supported by a top class Scientific Advisory Board with internationally recognized medical experts and surgeons as members.